scholarly journals Higher serum uric acid level is inversely associated with renal function assessed by cystatin C in a Japanese general population without chronic kidney disease: the KOBE study

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Sachimi Kubo ◽  
Yoko Nishida ◽  
Yoshimi Kubota ◽  
Aya Higashiyama ◽  
Daisuke Sugiyama ◽  
...  
Author(s):  
Shahida Akhter ◽  
A. S. M. Rizwan

Background: Hyperuricaemia is a metabolic marker of decreased renal function in chronic kidney disease (CKD). It increases cardiovascular, cerebrovascular and mortality risk in patients with CKD. Objectives: To estimate serum uric acid level in different stages of CKD. Methods: The present study was a cross sectional analytical study and was conducted in the Department of Physiology, Dhaka Medical College, Dhaka from July 2012 to June 2013 on 300 participants. They were divided into group A (150 control healthy participants) and group B (150 diagnosed cases of CKD). Serum creatinine and serum uric acid levels were measured by auto analyzer in Department of Pathology, Dhaka Medical College. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine level by Modification of Diet in Renal Disease (MDRD) equation. For statistical analysis unpaired Student “t” test, one way ANOVA test, Bonferroni test, Pearson’s correlation coefficient (r) test and Linear regression were performed using SPSS for windows version 20. Result: In this study, serum uric acid level was significantly (p<0.05) higher and eGFR were significantly lower in study groups than that of control group. There was gradual rise of serum uric acid level in CKD subjects from stage I to V. A significant inverse correlation was observed between serum uric acid level and eGFR. Serum uric acid level increased 0.048 mg/dl for each ml/min/1.73m2 decrease of eGFR. Conclusion: This study concludes that serum uric acid level increases gradually in accordance with the higher stages of CKD. There is a negative correlation of serum uric acid with eGFR in all stages of CKD which was statistically significant (p<0.05). Screening of serum uric acid level in different stages of CKD may be beneficial for assessing renal damage as well as prediction of co-morbidities associated with it.


2011 ◽  
Vol 33 (4) ◽  
pp. 298-304 ◽  
Author(s):  
Mehmet Kanbay ◽  
Mahmut Ilker Yilmaz ◽  
Alper Sonmez ◽  
Faruk Turgut ◽  
Mutlu Saglam ◽  
...  

2017 ◽  
Vol 266 ◽  
pp. 121-127 ◽  
Author(s):  
Yuta Matsukuma ◽  
Kosuke Masutani ◽  
Shigeru Tanaka ◽  
Akihiro Tsuchimoto ◽  
Naoki Haruyama ◽  
...  

2015 ◽  
Vol 65 (10) ◽  
pp. A1514
Author(s):  
Shin Kawasoe ◽  
Shiro Yoshifuku ◽  
Takuro Kubozono ◽  
Hironori Miyahara ◽  
Naoya Oketani ◽  
...  

e-CliniC ◽  
2017 ◽  
Vol 5 (2) ◽  
Author(s):  
Jonathan Moula ◽  
Emma Sy. Moeis ◽  
Cerelia Sugeng

Abstract: Chronic kidney disease (CKD) is a global public health problem. The CKD Epidemiology Collaboration (CKD-EPI) equation is the most accurate result of GFR (eGFR) that has been evaluated in large varied populations and can be applied clinically in general. In CKD patient, uric acid excretion decreases linearly along the worsening renal function. This study was aimed to determine the relationship between serum uric acid level based on eLFGCKD-EPI value and eGFR CKD-EPI in non-dialysis CKD patients (male and female). This was an analytical study with a cross-sectional design using medical record data of CKD patients at Prof. Dr. R. D. Kandou Hospital from January to December 2016. There were 82 samples who met the inclusion criteria. The results showed that 45 of 54 males and 27 of 28 females with non-dialysis CKD had elevated serum uric acid levels. The correlation test between serum uric acid level and eLFG CKD-EPI value on males and females were P=0.0; r=-0.473 and P=0.0; r=-0,598 respectively. Conclusion: There was a significant negative relationship between serum uric acid level and eLFG CKD-EPI value in non-dialysis CKD patients for both sexes. Based on eLFGCKD-EPI value, most patients had elevated serum uric acid levels.Keywords: non-dialysis chronic kidney disease, serum uric acid, eLFG CKD-EPI Abstrak: Penyakit ginjal kronik (PGK) merupakan masalah kesehatan masyarakat global. Persamaan CKD-EPI (CKD Epidemiology Collaboration) adalah persamaan estimasi LFG (eLFG) yang paling akurat dan telah dievaluasi pada populasi beragam dalam jumlah besar dan dapat diterapkan pada penggunaan klinis secara umum. Pada pasien PGK, ekskresi asam urat menurun secara linier seiring dengan memburuknya fungsi ginjal. Penelitian ini bertujuan untuk mengetahui hubungan kadar asam urat serum berdasarkan nilai eLFGCKD-EPI dan nilai eLFG CKD-EPI pada PGK non-dialisis (PGK-ND) baik pada jenis kelamin laki-laki maupun perempuan. Jenis penelitian ialah analitik dengan desain potong lintang menggunakan data rekam medik pasien PGK di RSUP Prof. Dr. R. D. Kandou periode Januari-Desember 2016. Terdapat 82 sampel yang memenuhi kriteria inklusi. Hasil penelitian mendapatkan 45 dari 54 laki-laki dan 27 dari 28 perempuan dengan PGK-ND mengalami peningkatan kadar asam urat serum. Uji korelasi hubungan antara kadar asam urat serum dan nilai eLFGCKD-EPI pada jenis kelamin laki-laki dan perempuan masing-masing P=0,0; r=-0,473 dan P=0,0; r=-0,598. Simpulan: Terdapat hubungan negatif bermakna antara kadar asam urat serum dan nilai eLFGCKD-EPI pada kedua jenis kelamin. Pada sebagian besar pasien PGK-ND baik laki-laki mupun perempuan terdapat peningkatan kadar asam urat serum berdasarkan nilai eLFGCKD-EPI.Kata kunci: penyakit ginjal kronis non-dialisis, asam urat serum, eLFG CKD-EPI


Author(s):  
Jinsu Deena Jose ◽  
Mathew George ◽  
Lincy Joseph

Chronic kidney disease is defined as the abnormality of the kidney structure or function for≥ 3 months and is associated with an irreversible reduction of the excretory and the endocrine functions of the kidney. An important risk factor for the development and progression of CKD is hyperuricemia. Hyperuricemia can occur as a result of the increased production or the reduced secretion of uric acid. Increased uric acid level is significantly associated with a greater decline in renal function and there is a higher risk of progression into kidney failure. Febuxostat is a nonpurine xanthine oxidase inhibitor for the treatment of hyperuricemia in patients with chronic kidney disease. It reduces serum uric acid concentrations by blocking the transformation of hypoxanthine to xanthine and xanthine to uric acid. Febuxostat is mainly metabolized in the liver and excreted through both urine and feces. Renal adjustment is also not required in CKD patients with mild to moderately reduced eGFR as it is metabolized mainly by glucuronidation and oxidation in the liver and well excreted by both urinary and fecal routes. Recent studies show that, in addition to lowering the uric acid level, febuxostat preserves the eGFR. Keywords:  Chronic kidney disease, hyperuricemia, febuxostat, eGFR


2020 ◽  
Vol 44 (1) ◽  
pp. 107-116 ◽  
Author(s):  
Kazuma Mori ◽  
Masato Furuhashi ◽  
Marenao Tanaka ◽  
Keita Numata ◽  
Takashi Hisasue ◽  
...  

Hypertension ◽  
2013 ◽  
Vol 62 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Jesse Dawson ◽  
Panniyammakal Jeemon ◽  
Lucy Hetherington ◽  
Caitlin Judd ◽  
Claire Hastie ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document